MARKET

ENGN

ENGN

enGene Therapeutics Inc
NASDAQ
1.720
+0.020
+1.18%
Pre Market: 1.720 0 0.00% 05:46 08/19 EDT
OPEN
1.700
PREV CLOSE
1.700
HIGH
1.740
LOW
1.690
VOLUME
3
TURNOVER
0
52 WEEK HIGH
12.25
52 WEEK LOW
1.400
MARKET CAP
115.22M
P/E (TTM)
-0.7888
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENGN last week (0810-0814)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)
TipRanks · 08/12 13:30
Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN) and Maze Therapeutics, Inc. (MAZE)
TipRanks · 08/12 11:00
Analyst Reaffirms Buy on enGene, Maintains $4 Price Target on Operational and Market Advantages for Detalimogene
TipRanks · 08/12 10:25
enGene highlights detalimogene NMIBC KOL insights and outlook
TipRanks · 08/11 20:38
Weekly Report: what happened at ENGN last week (0803-0807)?
Weekly Report · 08/10 09:09
Weekly Report: what happened at ENGN last week (0727-0731)?
Weekly Report · 08/03 09:09
Weekly Report: what happened at ENGN last week (0720-0724)?
Weekly Report · 07/27 09:10
More
About ENGN
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).

Webull offers enGene Therapeutics Inc stock information, including NASDAQ: ENGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGN stock methods without spending real money on the virtual paper trading platform.